Otolaryngologic Side Effects of GLP-1 Receptor Agonists.

Khan FI, Vazquez SG, Mehdi Z, Somawardana I, Dongre R, Razmi S, Rashidi K, Shenoi J, Khan N, Dhanda A, Takashima M, Ahmed OG

The Laryngoscope12 Feb 2025Cited by 11 (Europe PMC)

PMID39936458DOI10.1002/lary.32061PepBankPUB-39936458

Publisher page PubMedAsk about this study

Jump to 20 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

12 results from studies that gave the peptide. 12 results from people.

01HumanObservational studySafety outcome
In FAERS reports, dulaglutide showed a significant GERD reporting signal.
In plain wordsIn adverse event reports, dulaglutide was linked to a significant acid reflux reporting signal.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGERD reporting signal
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
This was followed by GERD which also had very high signal ratios and was significant in all drugs assessed.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
Report a problemFND-3993645809
02HumanObservational studySafety outcome
In FAERS reports, liraglutide showed a significant GERD reporting signal.
In plain wordsIn adverse event reports, liraglutide was linked to a significant acid reflux reporting signal.
Peptide
Liraglutide
Outcome
IncreaseGERD reporting signal
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
This was followed by GERD which also had very high signal ratios and was significant in all drugs assessed.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
Report a problemFND-3993645810
03HumanObservational studySafety outcome
In FAERS reports, semaglutide showed a significant GERD reporting signal.
In plain wordsIn adverse event reports, semaglutide was linked to a significant acid reflux reporting signal.
Peptide
Semaglutide
Outcome
IncreaseGERD reporting signal
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
This was followed by GERD which also had very high signal ratios and was significant in all drugs assessed.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
Report a problemFND-3993645811
04HumanObservational studySafety outcome
In FAERS reports, tirzepatide showed a significant GERD reporting signal.
In plain wordsIn adverse event reports, tirzepatide was linked to a significant acid reflux reporting signal.
Peptide
Tirzepatide
Outcome
IncreaseGERD reporting signal
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
This was followed by GERD which also had very high signal ratios and was significant in all drugs assessed.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
Report a problemFND-3993645812
05HumanObservational studySafety outcome
In FAERS reports, semaglutide showed a significant anosmia reporting signal.
In plain wordsIn adverse event reports, semaglutide was linked to a significant loss of smell reporting signal.
Peptide
Semaglutide
Outcome
IncreaseAnosmia reporting signal
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide also had significant signals in anosmia, dry mouth, dysgeusia, and Bell's palsy.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
Report a problemFND-3993645813
06HumanObservational studySafety outcome
In FAERS reports, semaglutide showed a significant dry mouth reporting signal.
In plain wordsIn adverse event reports, semaglutide was linked to a significant dry mouth reporting signal.
Peptide
Semaglutide
Outcome
IncreaseDry mouth reporting signal
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide also had significant signals in anosmia, dry mouth, dysgeusia, and Bell's palsy.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
Report a problemFND-3993645814
07HumanObservational studySafety outcome
In FAERS reports, semaglutide showed a significant dysgeusia reporting signal.
In plain wordsIn adverse event reports, semaglutide was linked to a significant altered taste reporting signal.
Peptide
Semaglutide
Outcome
IncreaseDysgeusia reporting signal
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide also had significant signals in anosmia, dry mouth, dysgeusia, and Bell's palsy.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
Report a problemFND-3993645815
08HumanObservational studySafety outcome
In FAERS reports, semaglutide showed a significant Bell's palsy reporting signal.
In plain wordsIn adverse event reports, semaglutide was linked to a significant Bell's palsy reporting signal.
Peptide
Semaglutide
Outcome
IncreaseBell's palsy reporting signal
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Semaglutide also had significant signals in anosmia, dry mouth, dysgeusia, and Bell's palsy.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
Report a problemFND-3993645816
09HumanObservational studySafety outcome
In FAERS reports, liraglutide showed significant dysphonia reporting signals.
In plain wordsIn adverse event reports, liraglutide was linked to significant voice disorder reporting signals.
Peptide
Liraglutide
Outcome
IncreaseDysphonia reporting signal
Study
n: not reported in source
Outcome group
Adverse events · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide had significance in both signals in dysphonia, dysgeusia, tinnitus, and Bell's palsy.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
Report a problemFND-3993645817
10HumanObservational studySafety outcome
In FAERS reports, liraglutide showed significant dysgeusia reporting signals.
In plain wordsIn adverse event reports, liraglutide was linked to significant altered taste reporting signals.
Peptide
Liraglutide
Outcome
IncreaseDysgeusia reporting signal
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide had significance in both signals in dysphonia, dysgeusia, tinnitus, and Bell's palsy.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
Report a problemFND-3993645818
11HumanObservational studySafety outcome
In FAERS reports, liraglutide showed significant tinnitus reporting signals.
In plain wordsIn adverse event reports, liraglutide was linked to significant tinnitus reporting signals.
Peptide
Liraglutide
Outcome
IncreaseTinnitus reporting signal
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide had significance in both signals in dysphonia, dysgeusia, tinnitus, and Bell's palsy.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
Report a problemFND-3993645819
12HumanObservational studySafety outcome
In FAERS reports, liraglutide showed significant Bell's palsy reporting signals.
In plain wordsIn adverse event reports, liraglutide was linked to significant Bell's palsy reporting signals.
Peptide
Liraglutide
Outcome
IncreaseBell's palsy reporting signal
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide had significance in both signals in dysphonia, dysgeusia, tinnitus, and Bell's palsy.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
Report a problemFND-3993645820

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In FAERS reports, GLP-1 drugs including dulaglutide showed high medullary thyroid carcinoma signals, significant in virtually all medications.
In plain wordsIn adverse event reports, GLP-1 drugs including dulaglutide showed high medullary thyroid cancer signals, significant in virtually all medications.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseClass-level medullary thyroid carcinoma reporting signals
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Source sentences
Summary
Medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) had the highest signals and were significant in virtually all medications.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3993645801
14HumanNot a test of Liraglutide aloneObservational studySafety outcome
In FAERS reports, GLP-1 drugs including liraglutide showed high medullary thyroid carcinoma signals, significant in virtually all medications.
In plain wordsIn adverse event reports, GLP-1 drugs including liraglutide showed high medullary thyroid cancer signals, significant in virtually all medications.
Peptide
Liraglutide
Outcome
IncreaseClass-level medullary thyroid carcinoma reporting signals
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Source sentences
Summary
Medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) had the highest signals and were significant in virtually all medications.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3993645802
15HumanNot a test of Semaglutide aloneObservational studySafety outcome
In FAERS reports, GLP-1 drugs including semaglutide showed high medullary thyroid carcinoma signals, significant in virtually all medications.
In plain wordsIn adverse event reports, GLP-1 drugs including semaglutide showed high medullary thyroid cancer signals, significant in virtually all medications.
Peptide
Semaglutide
Outcome
IncreaseClass-level medullary thyroid carcinoma reporting signals
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Source sentences
Summary
Medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) had the highest signals and were significant in virtually all medications.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3993645803
16HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In FAERS reports, GLP-1 drugs including tirzepatide showed high medullary thyroid carcinoma signals, significant in virtually all medications.
In plain wordsIn adverse event reports, GLP-1 drugs including tirzepatide showed high medullary thyroid cancer signals, significant in virtually all medications.
Peptide
Tirzepatide
Outcome
IncreaseClass-level medullary thyroid carcinoma reporting signals
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Source sentences
Summary
Medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) had the highest signals and were significant in virtually all medications.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3993645804
17HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In FAERS reports, GLP-1 drugs including dulaglutide showed high papillary thyroid carcinoma signals, significant in virtually all medications.
In plain wordsIn adverse event reports, GLP-1 drugs including dulaglutide showed high papillary thyroid cancer signals, significant in virtually all medications.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseClass-level papillary thyroid carcinoma reporting signals
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Source sentences
Summary
Medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) had the highest signals and were significant in virtually all medications.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3993645805
18HumanNot a test of Liraglutide aloneObservational studySafety outcome
In FAERS reports, GLP-1 drugs including liraglutide showed high papillary thyroid carcinoma signals, significant in virtually all medications.
In plain wordsIn adverse event reports, GLP-1 drugs including liraglutide showed high papillary thyroid cancer signals, significant in virtually all medications.
Peptide
Liraglutide
Outcome
IncreaseClass-level papillary thyroid carcinoma reporting signals
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Source sentences
Summary
Medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) had the highest signals and were significant in virtually all medications.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3993645806
19HumanNot a test of Semaglutide aloneObservational studySafety outcome
In FAERS reports, GLP-1 drugs including semaglutide showed high papillary thyroid carcinoma signals, significant in virtually all medications.
In plain wordsIn adverse event reports, GLP-1 drugs including semaglutide showed high papillary thyroid cancer signals, significant in virtually all medications.
Peptide
Semaglutide
Outcome
IncreaseClass-level papillary thyroid carcinoma reporting signals
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Source sentences
Summary
Medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) had the highest signals and were significant in virtually all medications.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3993645807
20HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In FAERS reports, GLP-1 drugs including tirzepatide showed high papillary thyroid carcinoma signals, significant in virtually all medications.
In plain wordsIn adverse event reports, GLP-1 drugs including tirzepatide showed high papillary thyroid cancer signals, significant in virtually all medications.
Peptide
Tirzepatide
Outcome
IncreaseClass-level papillary thyroid carcinoma reporting signals
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Source sentences
Summary
Medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) had the highest signals and were significant in virtually all medications.
2 context sentences(design, population, supporting numbers)
Summary · context
Retrospective analysis of national registry.
Summary · context
The Food and Drug Administration's Adverse Event Reporting System (FAERS) database was queried for events related to the GLP-1 RA: exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from 1 year after their approval until the end of 2023.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3993645808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 5Current
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 4
21 Oct 2026, 18:59 UTC
The same notice was added 3 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC